Showing results (121-130 of 253) with videos related to

Sort By:
Pageof 26
Leukemia & Lymphoma|April 16, 2014
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomideVittorio Montefusco, Monica Galli, Francesco Spina, et al.
British Journal of Haematology|April 25, 2022
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamicsEleonora Calabretta, Anna Guidetti, Francesca Ricci, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTORMaria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
British Journal of Haematology|September 10, 2023
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomasAnna Dodero, Stefania Bramanti, Martina Di Trani, et al.
Hematological Oncology|March 8, 2018
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleedingGiuseppe Boriani, Paolo Corradini, Antonio Cuneo, et al.
European Journal of Haematology|March 26, 2014
Experts' considerations on HLA-haploidentical stem cell transplantationFrancesca Patriarca, Leo Luznik, Marta Medeot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapyMarco Ladetto, Daniela Drandi, Mara Compagno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2007
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma NetworkAntonio Palumbo, Patrizia Falco, Paolo Corradini, et al.
Pageof 26